Pre-Series A Financing of Epitopea Inc. and Epitopea Limited

USD 31 million financing round to support the strategic development and clinical entry of cancer immunotherapeutics. 

BCF represented Epitopea Inc., a Canadian company, and Epitopea Limited, a UK company, in connection with a significant USD 31 million (GBP 24 million) financing round to support the expansion of Epitopea’s cancer immunotherapy research. 

This cross-border, pre-Series A preferred share financing round of Epitopea featured an exchangeable share structure. It was led by a syndicate of international investors including Advent Life Sciences, CTI Life Sciences, Cambridge Innovation Capital (CIC), the Fonds de solidarité des travailleurs et des travailleuses du Québec (FTQ), Investissement Québec, adMare BioInnovations (NEOMED Institute) and IRICoR. 

Epitopea stands out as an innovative, transatlantic biopharmaceutical company specializing in the development of off-the-shelf RNA-based cancer treatments. Epitopea is at the forefront of research into new and largely unexplored tumour-specific antigens with offices in Montreal, Canada, and Cambridge, UK.  

The financing round proceeds will be used to accelerate Epitopea’s development campaigns and facilitate its transition to a clinical-stage company with a focused commitment to delivering transformational off-the-shelf RNA cancer immunotherapy into the clinic in 2026. 

BCF is proud to have represented Epitopea with a team composed of Gino Martel, Luka Pavlovic, Kevin Vincelette, Jyoti Chakraborty, Marc-André Godard, David Beaulieu, Alessia Talarico and Jinelle Salloum.